LDXHF (Lumos Diagnostics Holdings) Capex-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Lumos Diagnostics Holdings's Capital Expenditure for the six months ended in Dec. 2024 was $-0.02 Mil. Its Revenue for the six months ended in Dec. 2024 was $6.31 Mil.

Hence, Lumos Diagnostics Holdings's Capex-to-Revenue for the six months ended in Dec. 2024 was 0.00.

Lumos Diagnostics Holdings Capex-to-Revenue Historical Data

The historical data trend for Lumos Diagnostics Holdings's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Capex-to-Revenue Chart

Lumos Diagnostics Holdings Annual Data

Trend

Jun22

Jun23

Jun24

Capex-to-Revenue

0.37

0.02

0.01

Lumos Diagnostics Holdings Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Capex-to-Revenue	Get a 7-Day Free Trial			-	0.03	-	0.01	-

Competitive Comparison of Lumos Diagnostics Holdings's Capex-to-Revenue

For the Medical Devices subindustry, Lumos Diagnostics Holdings's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Diagnostics Holdings's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lumos Diagnostics Holdings's Capex-to-Revenue falls into.

Lumos Diagnostics Holdings Capex-to-Revenue Calculation

Lumos Diagnostics Holdings's Capex-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.098)	/	11.131
	=	0.01

Lumos Diagnostics Holdings's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.017)	/	6.306
	=	0.00

Lumos Diagnostics Holdings (OTCPK:LDXHF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Lumos Diagnostics Holdings Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lumos Diagnostics Holdings Ltd (OTCPK:LDXHF) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

LDX:Australia

Address

2724 Loker Avenue West, Carlsbad, CA, USA, 92010

Website

https://www.lumosdiagnostics.com

Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services, and it operates across two geographical regions, the United States and Australia. and the majority of revenue is generated from the United States.

Lumos Diagnostics Holdings Headlines

From GuruFocus

Lumos Diagnostics Receives Authorization for CoviDx� SARS-CoV-2 Rapid Antigen Test in Canada

By Business Wire Business Wire • 11-03-2021

Lumos Diagnostics FY21 Full Year Results

By Business Wire Business Wire • 08-31-2021

Lumos Diagnostics Raises $63M AUD in ASX IPO

By Business Wire Business Wire • 07-08-2021

Dr. Jerome Adams, Former U.S. Surgeon General, Joins Lumos Diagnostics as a Strategic Healthcare Adviser

By Business Wire Business Wire • 09-14-2021

Economic Evaluation of Lumos Diagnostics' FebriDx� Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually

By Business Wire Business Wire • 10-06-2021